Search
for
Sort by
Research 31–60 of 32
- Oral Combination Treatment of Gefitinib (IressaTM) and Sasam-Kyeongokgo: Synergistic Effects on the NCI-H520 Tumor Cell Line
- The Cutaneous Epidermal Growth Factor Network: Can it be Translated Clinically to Stimulate Hair Growth? - eScholarship
- Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor
- Cutaneous Side Effects in Non-Small Cell Lung Cancer Patients Treated with Iressa (ZD1839), an Inhibitor of Epidermal Growth Factor
- A Case of Hair Change and Acneiform Eruption Induced by ZD1839 (Iressa$^{(R)}$)
- Acneiform eruptions caused by an epidermal growth factor receptor-tyrosine kinase inhibitor ZD 1839
- Hair disorders in patients with cancer
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- Cetuximab-Associated Elongation of the Eyelashes
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Plucked human hair as a tissue in which to assess pharmacodynamic end points during drug development studies
- Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- Management of Toxicities of Targeted Therapies
- Cutaneous Side Effects of Chemotherapy and Radiotherapy
- Hair Growth After Gefitinib Treatment
- Cutaneous drug reactions
- Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team
- PRIDE syndrome with lumbosacral hypertrichosis
- Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib
- Epidermal growth factor receptor inhibitors and hair
- Are all adverse effects undesirable? a case of chemotherapy induced adverse effect- an exception!?
- Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
- The Cutaneous Epidermal Growth Factor Network: Can it be Translated Clinically to Stimulate Hair Growth?
- Persistent hair growth during treatment with the EGFR inhibitor erlotinib
- EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management
- Cutaneous Lesions in the Rat Following Administration of an Irreversible Inhibitor of erbB Receptors, Including the Epidermal Growth Factor Receptor
- Role of anabolic agents in colorectal carcinogenesis: Myths and realities (Review)
- The Dark Side of Gefitinib: Reflectance Confocal Microscopy Applied to Hair Hyperpigmentation
- Treatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers